19
The Dr Jack Watters debate: Tackling antimicrobial resistance in an ageing society Wednesday, 16 th November 2016 This event is kindly supported by Pfizer #futureofAMR

16Nov16 - The Dr Jack Watters debate: Tackling antimicrobial resistance in an ageing society

  • Upload
    ilc-uk

  • View
    26

  • Download
    3

Embed Size (px)

Citation preview

The Dr Jack Watters debate: Tackling antimicrobial resistance in an

ageing society

Wednesday, 16th November 2016

This event is kindly supported by Pfizer

#futureofAMR

Welcome

Baroness Sally GreengrossChief Executive

ILC-UK

This event is kindly supported by Pfizer

#futureofAMR

Welcome

Paula DeColaSenior Director, Global Patient Affairs

Pfizer

This event is kindly supported by Pfizer

#futureofAMR

Professor David SalisburyAssociate Fellow

Centre for Global Health Security Chatham House

This event is kindly supported by Pfizer

#futureofAMR

Antimicrobial resistance in an ageing population

Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSciAssociate Fellow, Centre on Global Health Security,

Royal Institute for International Affairs, Chatham House, London.

Debate: The role of vaccines and antimicrobial resistance in an ageing population.

There is no debate!

Vaccines that we already use that are relevant to an ageing society.

Rotavirus vaccine for young children.Pneumococcal conjugate vaccine for young children.Meningococcal vaccines (C, B, Y, W)Haemophilus influenza b for young children.Influenza vaccine for children and risk groups.Varicella zoster vaccine

Haemophilus influenzae type b – Laboratory ReportsEngland 1990 - 2012

Very successful control of Invasive Hib Disease

Neisseria meningitidis type C (MenC). E&W;

1998 – 2009.

0

100

200

300400

500

600

700

800

1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

Year

Num

ber o

f Men

C c

ases

Under 20 years old

Over 20 years old

Introduction of the Meningococcal C vaccine

Source HPA

Impact of PCV 7 and 13

Cases in children >5 years

0

50

100

150

200

250

300

350

400

450

500

1997/8 1998/9 1999/0 2000/1 2001/2 2002/3 2003/4 2004/5 2005/6 2006/7 2007/8 2008/9

Epidemiological year

Num

ber o

f Cas

es

4, 6B, 9V, 14, 18C, 19F and 23F serotypes contained in Prevenar and Prevenar 13Prevenar introduced into the routine childhood immunisation schedule in 2006

Source HPA

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/503291/Norovirus_update_2016_week_06.pdf

Vaccines that we may use that are relevant to an ageing society.

RSV vaccine for children and older ages.Staph. aureusC. difficileE. coliNorovirus (children, risk groups, older individuals)PseudomonasKlebsiella

Alzheimer’sDiabetesCancer vaccines

Debate: The role of vaccines in antimicrobial resistance in an ageing population

Why have vaccines not received a higher profile?

Matthew EdwardsHead of Mortality and Longevity

Willis Towers Watson

This event is kindly supported by Pfizer

#futureofAMR

Michelle BresnahanCo-Founder

A Life for a Cure

This event is kindly supported by Pfizer

#futureofAMR

Panel DiscussionMichelle Bresnahan

Co-FounderA Life for a Cure

This event is kindly supported by Pfizer

#futureofAMR

Prof David SalisburyAssociate Fellow, Centre for Global

Health Security Chatham House

Dr Gina RadfordDeputy Chief Medical Officer

Close

Baroness Sally GreengrossChief Executive

ILC-UK

This event is kindly supported by Pfizer

#futureofAMR

The Dr Jack Watters debate: Tackling antimicrobial resistance in an

ageing society

Wednesday, 16th November 2016

This event is kindly supported by Pfizer

#futureofAMR